ADHFAcute Decompensated Heart Failure
ADHFAmerican Digestive Health Foundation
ADHFAgility Dog Hall of Fame (golden retrievers)
References in periodicals archive ?
From 2005 to 2010, the average estimated number of ADHF hospitalisations in the US was 1.
Concentrations of sST2 are not useful for diagnostic evaluation of ADHF (12) but they do have strong prognostic value.
This finding is consistent with the results of an important Italian study showing that worsening renal function alone isn't independently associated with increased risk of death or ADHF readmission; the problems arise in patients with worsening renal function and persistent congestion (Circ Heart Fail.
5 mL/kg/h for at least 6 hours), and, in patients of Group B, using the threshold value of NGAL plasma levels of 200 ng/mL, which represents one of the most accurate cut-off in AKI diagnosis for ADHF patients (21).
The primary purpose of this paper is to illustrate the use of the 6MWT in the evaluation of functional capacity and prescription of interval exercise in a patient with ADHF receiving tailored therapy with dobutamine.
at a cost of over $33 billion, ADHF is one of our country's most expensive health problems," said Richard B.
We recently reported a blinded evaluation of NT-proBNP in 599 patients with acute dyspnea (5) demonstrating the importance of this biomarker for diagnosis or exclusion of ADHF in these subjects.
He disclosed that he was an investigator in the studies that led to nesiritide's FDA approval for treatment of ADHF.
Trevena is developing TRV027 for the intravenous hospital treatment of acute decompensated heart failure (ADHF), and these data support the advancement of TRV027 into a future study to evaluate its clinical efficacy in patients with ADHF.
An expert panel of physicians trained in cardiovascular medicine reviewed the presenting signs and symptoms, medical history, medications, echocardiography, and electrocardiograms to diagnose ADHF by use of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial criteria (13).
a clinical stage pharmaceutical company developing therapeutic agents for the treatment of acute decompensated heart failure (ADHF) and other cardiovascular diseases, announced the presentation of a comprehensive review of the pharmacological effects of nitroxyl (HNO) in the treatment of ADHF.
hospitalizations per year with ADHF as the primary or secondary diagnosis.